Berberine ameliorates inflammation in patients with acute coronary syndrome following percutaneous coronary intervention

Clinical and Experimental Pharmacology and Physiology

Volumn 39, Issue 5, 2012, Pages 406-411

  Meng, Shu ^a   Wang, Lian Sheng ^b   Huang, Zhou Qing ^b   Zhou, Qing ^a   Sun, Ying Gang ^a   Cao, Jia Tian ^c   Li, Yi Gang ^a   Wang, Chang Qian ^c  

^a XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^c WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Acute coronary syndrome; Berberine; Inflammation; Lipids; Percutaneous coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BERBERINE; C REACTIVE PROTEIN; CLOPIDOGREL; GELATINASE B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1;

ABDOMINAL PAIN; ACUTE CORONARY SYNDROME; ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ERUPTION; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ACUTE CORONARY SYNDROME; AGED; ANGIOPLASTY, BALLOON, CORONARY; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BERBERINE; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84860247898     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2012.05670.x     Document Type: Article

References (46)

1. Fuster V, Moreno PR, Fayad ZA, Corti R, Badimon JJ. Atherothrombosis and high-risk plaque: part I. Evolving concepts. J. Am. Coll. Cardiol. 2005; 46: 937-54.
2. Schwartz RS, Holmes DR Jr, Topol EJ. The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J. Am. Coll. Cardiol. 1992; 20: 1284-93.
3. Rodgers GP, Minor ST, Robinson K et al. The coronary artery response to implantation of a balloon-expandable flexible stent in the aspirin- and non-aspirin-treated swine model. Am. Heart J. 1991; 122: 640-7.
4. Patti G, Chello M, Pasceri V et al. Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy. J. Am. Coll. Cardiol. 2006; 48: 1560-6.
5. Kereiakes DJ. Adjunctive pharmacotherapy before percutaneous coronary intervention in non-ST-elevation acute coronary syndromes: the role of modulating inflammation. Circulation 2003; 108 (16 Suppl. 1): III-22-7.
6. Toutouzas K, Colombo A, Stefanadis C. Inflammation and restenosis after percutaneous coronary interventions. Eur. Heart J. 2004; 25: 1679-87.
7. Ikeda U. Inflammation and coronary artery disease. Curr. Vasc. Pharmacol. 2003; 1: 65-70.
8. Sposito AC, Chapman MJ. Statin therapy in acute coronary syndromes: mechanistic insight into clinical benefit. Arterioscler. Thromb. Vasc. Biol. 2002; 22: 1524-34.
9. Patti G, Pasceri V, Colonna G et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J. Am. Coll. Cardiol. 2007; 49: 1272-8.
10. Hao PP, Chen YG, Wang JL et al. Meta-analysis of the role of high-dose statins administered prior to percutaneous coronary intervention in reducing major adverse cardiac events in patients with coronary artery disease. Clin. Exp. Pharmacol. Physiol. 2010; 37: 496-500.
11. Paragh G, Fulop P. Impact of lipid lowering therapy on liver function. Orv. Hetil. 2009; 150: 1205-12 (in Hungarian).
12. Ikram M. A review on the chemical and pharmacological aspects of genus Berberis. Planta Med. 1975; 28: 353-8.
13. Choi SH, Cho SK, Kang SS et al. Effect of apitherapy in piglets with preweaning diarrhea. Am. J. Chin. Med. 2003; 31: 321-6.
14. Anis KV, Rajeshkumar NV, Kuttan R. Inhibition of chemical carcinogenesis by berberine in rats and mice. J. Pharm. Pharmacol. 2001; 53: 763-8.
15. Stermitz FR, Lorenz P, Tawara JN, Zenewicz LA, Lewis K. Synergy in a medicinal plant: antimicrobial action of berberine potentiated by 5′-methoxyhydnocarpin, a multidrug pump inhibitor. Proc. Natl Acad. Sci. USA 2000; 97: 1433-7.
16. Chen FL, Yang ZH, Liu Y et al. Berberine inhibits the expression of TNFalpha, MCP-1, and IL-6 in AcLDL-stimulated macrophages through PPARgamma pathway. Endocrine 2008; 33: 331-7.
17. Guo Y, Wang QZ, Li FM, Jiang X, Zuo YF, Wang L. Biochemical pathways in the antiatherosclerotic effect of berberine. Chin. Med. J. 2008; 121: 1197-203.
18. Huang Z, Wang L, Meng S, Wang Y, Chen T, Wang C. Berberine reduces both MMP-9 and EMMPRIN expression through prevention of p38 pathway activation in PMA-induced macrophages. Int. J. Cardiol. 2011; 146: 153-8.
19. Jeong HW, Hsu KC, Lee JW et al. Berberine suppresses proinflammatory responses through AMPK activation in macrophages. Am. J. Physiol. Endocrinol. Metab. 2009; 296: E955-64.
20. Nam CW, Mangiacapra F, Entjes R et al. Functional SYNTAX score for risk assessment in multivessel coronary artery disease. J. Am. Coll. Cardiol. 2011; 58: 1211-8.
21. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-43.
22. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ. Res. 2001; 89: 763-71.
23. de Lemos JA, Morrow DA, Sabatine MS et al. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation 2003; 107: 690-5.
24. Bayata S, Arikan E, Yesil M, Postaci N, Tas A, Koseoglu M. An important role for VCAM-1, but not for ICAM-1 in restenosis following coronary stent implantation. Anadolu Kardiyol. Derg. 2010; 10: 405-9.
25. Blake GJ, Ridker PM. C-Reactive protein and other inflammatory risk markers in acute coronary syndromes. J. Am. Coll. Cardiol. 2003; 41(Suppl.): S37-42.
26. Frazier L, Vaughn WK, Willerson JT, Ballantyne CM, Boerwinkle E. Inflammatory protein levels and depression screening after coronary stenting predict major adverse coronary events. Biol. Res. Nurs. 2009; 11: 163-73.
27. Meigs JB, Hu FB, Rifai N, Manson JE. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA 2004; 291: 1978-86.
28. - microparticles is associated with improvement of endothelial function in humans. Eur. J. Pharmacol. 2009; 614: 77-83.
29. Affuso F, Ruvolo A, Micillo F, Sacca L, Fazio S. Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study. Nutr. Metab. Cardiovasc. Dis. 2010; 20: 656-61.
30. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102: 2165-8.
31. Moreno PR, Bernardi VH, Lopez-Cuellar J et al. Macrophages, smooth muscle cells, and tissue factor in unstable angina. Implications for cell-mediated thrombogenicity in acute coronary syndromes. Circulation 1996; 94: 3090-7.
32. Libby P. Changing concepts of atherogenesis. J. Intern. Med. 2000; 247: 349-58.
33. Newby AC. Metalloproteinases and vulnerable atherosclerotic plaques. Trends Cardiovasc. Med. 2007; 17: 253-8.
34. Schwartz GG, Olsson AG, Ezekowitz MD et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285: 1711-8.
35. Dimitrow PP, Jawien M. Anti-inflammatory effect of atorvastatin in patients with aortic sclerosis or mild aortic stenosis independent of hypercholesterolemia. Pharmacol. Rep. 2010; 62: 1250-4.
36. Meredith IT, Plunkett JC, Worthley SG, Hope SA, Cameron JD. Systemic inflammatory markers in acute coronary syndrome: association with cardiovascular risk factors and effect of early lipid lowering. Coron. Artery Dis. 2005; 16: 415-22.
37. Millar JS, Ky B, Wolfe ML, Pruscino L, Baer A, Rader DJ. Short-term treatment with high-dose atorvastatin reduces LDL cholesterol but shows no anti-inflammatory effects in normolipidemic subjects with normal CRP levels. Clin. Transl. Sci. 2010; 3: 140-6.
38. Zhang Q, Xiao X, Feng K et al. Berberine moderates glucose and lipid metabolism through multipathway mechanism. Evid. Based Complement. Alternat. Med. 2011; 2011: Pii: 92485.
39. Kong W, Wei J, Abidi P et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat. Med. 2004; 10: 1344-51.
40. Lee S, Lim HJ, Park JH, Lee KS, Jang Y, Park HY. Berberine-induced LDLR up-regulation involves JNK pathway. Biochem. Biophys. Res. Commun. 2007; 362: 853-7.
41. Doggrell SA. Berberine: a novel approach to cholesterol lowering. Expert Opin. Invest. Drugs 2005; 14: 683-5.
42. Hsieh YS, Kuo WH, Lin TW et al. Protective effects of berberine against low-density lipoprotein (LDL) oxidation and oxidized LDL-induced cytotoxicity on endothelial cells. J. Agric. Food. Chem. 2007; 55: 10437-45.
43. Zhou L, Yang Y, Wang X et al. Berberine stimulates glucose transport through a mechanism distinct from insulin. Metabolism 2007; 56: 405-12.
44. Lee YS, Kim WS, Kim KH et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 2006; 55: 2256-64.
45. Zhang H, Wei J, Xue R et al. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism 2009; 59: 285-92.
46. Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism 2008; 57: 712-7.